AbCellera Biologics
ABCL
ABCL
127 hedge funds and large institutions have $370M invested in AbCellera Biologics in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
5.83% less ownership
Funds ownership: 41.84% → 36.02% (-5.8%)
18% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 44
Holders
127
Holding in Top 10
–
Calls
$3.46M
Puts
$1.81M
Top Buyers
| 1 | +$8.67M | |
| 2 | +$4.89M | |
| 3 | +$3.69M | |
| 4 |
Two Sigma Investments
New York
|
+$3.38M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.71M |
Top Sellers
| 1 | -$24.7M | |
| 2 | -$23.7M | |
| 3 | -$6.28M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.61M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.07M |
